Keytruda blocks the interaction of this protein with another protein called programmed death ligand-1 (PD-L1). The interaction between these two proteins stops some specific actions of your immune ...

Keytruda is not for everyone ... Whenever immune cells with PD-1 on the surface detect other cells with PD-L1 on their ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

Improved major pathological response was observed, with a trend towards better overall survival, though not statistically significant for high PD-L1 expression tumors. The safety profile of Keytruda ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

PD-L1 is the biomarker most often used for patient selection for checkpoint inhibitors, the most successful class of cancer drugs including Keytruda and Opdivo. The FDA sought the ODAC’s opinion ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

Crescent Biopharma is advancing a drug its CEO claims is “purpose-built” to be a perfected version of Summit Therapeutics’ ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding ...

Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding regulatory preparations for the trial design Efti ...